Pfizer reveals boost with €28.4bn in global vaccine sales likely this year

Vaccine on course to become one of the best-selling medicines of all time

A resurgence of virus infections thanks to the Delta variant is likely to mean sustained demand for vaccines globally. File picture

Pfizer now expects its Covid-19 vaccine to bring in $33.5bn (€28.4bn) in revenues this year, putting it on course to become one of the best-selling medicines of all time.

The drugmaker had previously projected vaccine sales for the year of $26bn and the upward revision is a sign demand for the shots, which Pfizer sells with German partner BioNTech, is surging as countries battle new outbreaks fuelled by the Delta virus variant.